USA flag logo/image

An Official Website of the United States Government

Novel Antifungals by Engineering the AbA NRPS gene

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
71263 		Program Year/Program:
2004 / SBIR
Agency Tracking Number:
AI061864 		Solicitation Year:
N/A 		Solicitation Topic Code:
N/A 		Solicitation Number:
N/A
Small Business Information
AUREOGEN BIOSCIENCES, INC.
6475 Technology Avenue, Ste C KALAMAZOO, MI 49009-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: Novel Antifungals by Engineering the AbA NRPS gene
Agency: HHS
Contract: 1R43AI061864-01
Award Amount: $162,982.00
 

Abstract:

DESCRIPTION (provided by applicant): There is an immediate need for efficient, novel antifungal drugs. The fungus Aureobasidium pullulans produces a cyclic peptide know as Aureobasidin A (AbA) which is a very potent, fungicidal drug that is currently barred from commercialization due to a requirement for modifications involving complex and expensive synthetic chemistry. The overall goal of the project described in this application is to (genetically) engineer A. pullulans to produce cyclic peptides that are, or can be developed into, well-tolerated, potent, broad spectrum antifungal drugs, using no synthetic chemistry or synthetic chemistry limited to a single substitution. Phase I of the project involves the identification, cloning, sequencing and mapping of the gene encoding the non-ribosomal peptide synthetase (NRPS) complex responsible for the synthesis of native AbA in A. pullulans. Determination of the complete NRPS gene sequence will allow identification and mapping of the biosynthetic modules and domains in the complex and thereby elucidation of the assembly sequence of the native compound. This information together with the cloned gene will provide the tools required to carry out the Phase II research plan. Phase II will involve altering the native NRPS complex gene by modifying or switching the biosynthetic modules and domains thereby generating organisms capable of producing novel cyclic peptides requiring minimal chemistry to become potent broad-spectrum antifungal drugs.

Principal Investigator:

Ake P. Elhammer
2693723517
AKE.P.ELHAMMER@AUREOGEN.COM

Business Contact:


2693723517
Small Business Information at Submission:

AUREOGEN BIOSCIENCES, INC.
4717 CAMPUS DRIVE SUITE 1200 KALAMAZOO, MI 49008

EIN/Tax ID: 200182587
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No